Novo Nordisk A/S (NYSE:NVO) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,074,876 shares of the company’s stock after purchasing an additional 80,070 shares during the period. Novo Nordisk A/S comprises approximately 0.7% of Natixis Advisors LLC’s investment portfolio, making the stock its 19th biggest holding. Natixis Advisors LLC owned approximately 0.07% of Novo Nordisk A/S worth $366,125,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Blair William & Co. IL raised its position in shares of Novo Nordisk A/S by 12.9% in the first quarter. Blair William & Co. IL now owns 71,036 shares of the company’s stock worth $9,121,000 after acquiring an additional 8,126 shares during the period. Nwam LLC raised its position in shares of Novo Nordisk A/S by 51.3% in the first quarter. Nwam LLC now owns 3,831 shares of the company’s stock worth $488,000 after acquiring an additional 1,299 shares during the period. First Foundation Advisors raised its position in shares of Novo Nordisk A/S by 3.1% in the first quarter. First Foundation Advisors now owns 7,416 shares of the company’s stock worth $952,000 after acquiring an additional 223 shares during the period. Nicolet Advisory Services LLC raised its position in shares of Novo Nordisk A/S by 5.2% in the first quarter. Nicolet Advisory Services LLC now owns 2,777 shares of the company’s stock worth $347,000 after acquiring an additional 138 shares during the period. Finally, Spirepoint Private Client LLC acquired a new position in shares of Novo Nordisk A/S in the first quarter worth about $271,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on NVO shares. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Stock Down 3.4 %

Shares of NYSE NVO opened at $101.74 on Friday. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The stock has a market cap of $456.56 billion, a PE ratio of 32.93, a P/E/G ratio of 1.31 and a beta of 0.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average of $118.58 and a 200 day moving average of $129.58.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.